Routine Gene Testing For Plavix Patients Unsupported By Evidence - ACC/AHA

While a small minority of cardiologists has embraced genetic testing for clopidogrel, FDA's warning that 2% - 14% of patients may not respond caused pushback from many in the field who argue it is not clear what steps to take when a patient is identified as a poor metabolizer.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet